Tradestie Institutional Equity Comparison Engine
CLYM vs CAMP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Overall Edge
CLYM Captures Institutional Edge (2โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CAMP at N/M Forward P/E and -991.8% operating margin (+138.9% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CAMP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CLYM N/M vs CAMP N/M Fwd P/E
Growth & Margin Winner
CLYM
Op Margin 0.0% vs -991.8% ยท YoY +0.0% vs +138.9%
Momentum & Technical Winner
CLYM
1Y +407.4% vs -2.4% ยท 52W Pos 48% vs 23%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.64
-3.02% 1D
Market Cap
$608.5M
1M Return
-0.92%
1Y Return
+407.37%
Forward P/E
N/M
Unified AI Score
45.7 / 100
HOLD
Tech 41.0
Fund 47.0
Flow 50.0
Mom 54.0
CAMP
NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$4.00
+3.63% 1D
Market Cap
$238.5M
1M Return
+27.39%
1Y Return
-2.44%
Forward P/E
N/M
Unified AI Score
43.9 / 100
HOLD
Tech 34.0
Fund 40.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CLYM +407.37%
CAMP -2.44%
Spread: +409.81 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CLYM TTM Op. Margin: 0.0%
CAMP TTM Op. Margin: -991.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs CAMP. Trailing 12-month operating profitability (CLYM 0.0% vs CAMP -991.8%) and valuation multiples (CLYM N/M vs CAMP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CLYM | CAMP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $608.5M | $238.5M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +138.9% | Higher Growth | CAMP |
| Operating Margin (TTM) Profitability | 0.0% | -991.8% | Higher Margin | CLYM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -29.3% | -146.1% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 48% ($2โ$18) | 23% ($3โ$8) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 112% Vol | 1.35ฮฒ ยท 94% Vol | Lower Realized Risk | CAMP |
| Unified Institutional Score Composite Signal | 45.7 / 100 (HOLD) | 43.9 / 100 (HOLD) | Higher Composite | CLYM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CLYM vs CAMP Buy Guide
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CAMP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CLYM nor CAMP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.